Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Publication
, Journal Article
Byrne, BJ; Garst, J
Published in: Curr Oncol Rep
July 2005
The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration, whereas cetuximab is being studied for use in NSCLC. Erlotinib has shown a survival advantage in patients with advanced NSCLC. Further studies have identified female sex, nonsmokers, Asian race, good performance status, and adenocarcinoma histology as predictors of patient response to these agents. A genetic mutation in EGFR has also been correlated with an increase in response.
Duke Scholars
Published In
Curr Oncol Rep
DOI
ISSN
1523-3790
Publication Date
July 2005
Volume
7
Issue
4
Start / End Page
241 / 247
Location
United States
Related Subject Headings
- Survival Analysis
- Quinazolines
- Protein Kinase Inhibitors
- Prognosis
- Oncology & Carcinogenesis
- Middle Aged
- Male
- Lung Neoplasms
- Humans
- Gefitinib
Citation
APA
Chicago
ICMJE
MLA
NLM
Byrne, B. J., & Garst, J. (2005). Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep, 7(4), 241–247. https://doi.org/10.1007/s11912-005-0045-6
Byrne, Brian J., and Jennifer Garst. “Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.” Curr Oncol Rep 7, no. 4 (July 2005): 241–47. https://doi.org/10.1007/s11912-005-0045-6.
Byrne BJ, Garst J. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep. 2005 Jul;7(4):241–7.
Byrne, Brian J., and Jennifer Garst. “Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.” Curr Oncol Rep, vol. 7, no. 4, July 2005, pp. 241–47. Pubmed, doi:10.1007/s11912-005-0045-6.
Byrne BJ, Garst J. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep. 2005 Jul;7(4):241–247.
Published In
Curr Oncol Rep
DOI
ISSN
1523-3790
Publication Date
July 2005
Volume
7
Issue
4
Start / End Page
241 / 247
Location
United States
Related Subject Headings
- Survival Analysis
- Quinazolines
- Protein Kinase Inhibitors
- Prognosis
- Oncology & Carcinogenesis
- Middle Aged
- Male
- Lung Neoplasms
- Humans
- Gefitinib